Clinical Trials Logo

Alcoholic Hepatitis clinical trials

View clinical trials related to Alcoholic Hepatitis.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT02116556 Enrolling by invitation - Alcoholic Hepatitis Clinical Trials

Effects of Rifaximin in Patients With Acute Alcoholic Hepatitis

RIFA-AAH
Start date: April 2013
Phase: Phase 2
Study type: Interventional

Acute alcoholic hepatitis (AAH) is a serious condition and one of the most frequent causes of Acute-on-Chronic Liver Failure. The current standard therapy (corticosteroids) is theme of debate and unsatisfactory in many patients (year mortality: 30%). One of the main causes of death is bacterial infections, which affect 40-50% of patients at 90 days. Intestinal decontamination with rifaximin (a nonabsorbable antibiotic) reduces endotoxemia, improves liver function and reduces the complications of decompensated alcoholic cirrhosis. The Hypothesis/Objective: To assess whether oral decontamination with rifaximin prevents the development of infections associated with AAH and analyze its consequences.